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Oxaliplatin plus fluorouracil/folinic acid (5-FU/FA) every 2 weeks has shown promising activity in advanced gastric cancer. This study
assessed the efficacy and safety of weekly oxaliplatin plus 5-FU/FA (FUFOX regimen) in the metastatic setting. Patients with
previously untreated metastatic gastric cancer received oxaliplatin (50mgm
 2) plus FA (500mgm
 2, 2-h infusion) followed by 5-FU
(2000mgm
 2, 24-h infusion) given on days 1, 8, 15 and 22 of a 5-week cycle. The primary end point of this multicentre phase II study
was the response rate according to RECIST criteria. A total of 48 patients were enrolled. Median age was 62 years and all patients
had metastatic disease, with a median number of three involved organs. The most common treatment-related grade 3/4 adverse
events were diarrhoea (17%), deep vein thrombosis (15%), neutropenia (8%), nausea (6%), febrile neutropenia (4%), fatigue (4%),
anaemia (4%), tumour bleeding (4%), emesis (2%), cardiac ischaemia (2%) and pneumonia (2%). Grade 1/2 sensory neuropathy
occurred in 67% of patients but there were no episodes of grade 3 neuropathy. Intent-to-treat analysis showed a response rate of
54% (95% CI, 39–69%), including two complete responses. At a median follow-up of 18.1 months (range 11.2–26.2 months),
median survival is 11.4 months (95% CI, 8.0–14.9 months) and the median time to progression is 6.5 months (95% CI, 3.9–9.2
months). The weekly FUFOX regimen is well tolerated and shows notable activity as first-line treatment in metastatic gastric cancer.
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Systemic chemotherapy has been shown to prolong survival and to
relieve symptoms in advanced gastric cancer (Glimelius et al,
1997). However, the number of patients who benefit from
treatment is still limited and the optimal chemotherapy regimen
has not yet been defined. Platinum-free regimens exhibited
disappointing efficacy in randomised trials. Cisplatin-based regi-
mens, for example the combination of epirubicin, cisplatin, and
5-FU (ECF), have demonstrated superior efficacy, albeit with
significant toxicity and inconvenience from the patients’ perspec-
tive (Waters et al, 1999; Vanhoefer et al, 2000).
Oxaliplatin is a third-generation diaminocyclohexane platinum
compound proven in numerous clinical trials to be active in
various tumour types. In advanced colorectal cancer, treatment
with oxaliplatin plus 5-fluorouracil/folinic acid (5-FU/FA) led to
significantly increased overall survival and progression-free
survival compared with former standard regimens (de Gramont
et al, 2000; Giacchetti et al, 2000; Goldberg et al, 2004). Therefore,
in many countries this combination forms the new standard of
care in the first-line treatment of metastatic disease. In advanced
gastric cancer, biweekly oxaliplatin plus 5-FU/FA has shown
considerable antitumour activity in phase II trials (Louvet et al,
2002a; Al-Batran et al, 2004). Oxaliplatin shows a better toxicity
profile than cisplatin. Its main and dose-limiting toxicity is acute,
cumulative peripheral sensory neurotoxicity, resulting in acral
paresthaesia and dysesthaesia, which are exacerbated by cold.
The weekly application of oxaliplatin plus infusional 5-FU/FA
(FUFOX), as proposed by the Arbeitsgemeinschaft Internistische
Onkologie (AIO), has proven to be highly effective in first-line
metastatic colorectal cancer. The AIO FUFOX regimen is also
associated with an acceptable toxicity profile, with a particularly
low rate of sensory neuropathy (Grothey et al, 2002).
This phase II trial was designed to assess the efficacy and safety
of the weekly combination of oxaliplatin plus infusional 5-FU/FA
(FUFOX) in first-line metastatic gastric cancer.
METHODS
Patient population
To be eligible for this study, patients had to have histologically
confirmed metastatic adenocarcinoma of the stomach or
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soesophagogastric junction. At least one measurable lesion
previously untreated with radiotherapy had to be present. No
prior treatment for advanced disease was allowed. Patients were
allowed to have received prior adjuvant or neoadjuvant chemo-
therapy/chemoradiation, providing that treatment had been
completed X6 months before inclusion in the study. All patients
were 418 years of age with an ECOG performance status p2 and a
life expectancy of X12 weeks.
Patients were required to have adequate bone marrow, renal and
hepatic function, defined as an absolute neutrophil count (ANC)
X1500ml, platelets X100000ml, S-creatinineo1.5 upper limit
of normal (ULN), total bilirubinp1.5 ULN, SGOT and/or
SGPTp1.5 ULN (p5.0 ULN in the presence of liver meta-
stasis). Patients with any central nervous system metastases or
neuropathy Xgrade 2 were excluded.
Pretreatment evaluation included signed written informed
consent, complete history and physical examination, laboratory
tests, CT scans of all areas affected by the tumour and an ECG. A
urine or serum pregnancy test was performed in female patients
of child-bearing age. All patients gave written informed consent
before enrolment and the study was approved by the ethics
committee for human research at the Technical University of
Munich. The study conformed to the principles of the Declaration
of Helsinki and its subsequent amendments.
Treatment plan
Oxaliplatin (50mgm
 2) was administered simultaneously with FA
(500mgm
 2) as a 2-h intravenous infusion, followed immediately
by 5-FU (2000mgm
 2) as a continuous infusion over 24h.
Treatment was repeated every week. One cycle of treatment was
defined as 4 weeks of treatment followed by 1 week of rest. In order
to avoid severe neurotoxicity, administration of oxaliplatin was
limited to every other week in patients receiving more than four
cycles. Patients were treated until best response or until there was
evidence of disease progression. Patients going off study were
allowed to receive any second-line treatment as determined
appropriate by their oncologist.
Study evaluations
A baseline CT was performed within 2 weeks prior to study
inclusion. After every second cycle of therapy, patients underwent
follow-up CT scans for assessment of response according to
RECIST criteria (Therasse et al, 2000). In cases where treatment
was discontinued before tumour progression, CT scans were
repeated every 3 months. Responses were to be confirmed within 4
weeks and were reviewed centrally by one independent radiologist
(J Stollfuss). Patients were considered evaluable for response if
they had received at least two cycles (10 weeks) of treatment, with
at least one follow-up tumour assessment. Nonevaluable patients
were included into the intention-to-treat analyses but reported as
being not evaluable.
Patients were monitored every week for laboratory parameters
and adverse events. With the exception of peripheral sensory
neuropathy, all adverse events were graded using the National
Cancer Institute Common Toxicity Criteria (NCI-CTC, version
2.0). Peripheral sensory neuropathy was graded according to a
modified oxaliplatin-specific scale (Caussanel et al, 1990): grade 1
– paresthaesias/dysesthaesias of short duration with complete
recovery before the next cycle; grade 2 – paresthaesias/dysesthae-
sias persisting between two cycles without functional impairment;
grade 3 – permanent paresthaesias/dysesthaesias resulting in
functional impairment. Patients going off study for reasons other
than disease progression were evaluated every 3 months during
follow-up visits.
Statistical considerations
The primary end point of this investigator-initiated, multicentre,
nonrandomised, open-label, phase II study was to determine the
proportion of patients responding to weekly FUFOX. The required
number of patients for this trial was calculated according to the
Simon two-stage design (Machin and Campbell, 1997), assuming a
minimal response rate (p0) of 30% and a worthwhile-to-detect-
response-rate (p1) of at least 50%. With a power of 80% and a
significance level of 5% for testing the hypothesis H0: prp0 vs H1:
pXp1, this resulted in a sample size of 15 for the first stage. If more
than five out of 15 were observed, another 31 patients were to be
recruited in the second stage. The drug combination was to be
rejected if less than 19 out of 46 patients were observed.
All eligible patients were included in the response, safety
and survival analyses. Time to progression (TTP: time from
study entry until documented tumour progression) and overall
survival (OS: time from study entry until death) were analysed
according to the Kaplan–Meier method, and were updated to
15 October 2004. Statistical computations were performed using
SPSS (version 12.0).
RESULTS
Patient characteristics
A total of 48 patients were enrolled at nine study sites between
August 2002 and November 2003. Patient baseline characteristics
are listed in Table 1. All patients had metastatic disease, with the
liver, lymph nodes, peritoneum and lung being the predominant
sites of metastases. The median number of involved organs was
three (range 0–5). In total, 37 (77%) patients had newly diagnosed
Table 1 Patient baseline characteristics
Characteristics
Total number of patients 48
Median age (range) 62 (41–75) years
Gender
Male 39 (81%)
Female 9 (19%)
ECOG performance status
0 23 (48%)
1 24 (50%)
2 1 (2%)
Disease status
Newly diagnosed 37 (77%)
Recurrent 11 (23%)
Locally advanced 0 (0%)
Metastatic 48 (100%)
Localisation of the primary tumour
Stomach 23 (48%)
Oesophagogastric junction 23 (48%)
Gastric stump 2 (4%)
Sites of disease
Liver 30 (63%)
Lymph nodes 29 (60%)
Peritoneum 16 (33%)
Lung 13 (27%)
Bone 5 (10%)
Others
a 6 (12%)
ECOG¼Eastern Cooperative Oncology Group.
aSkin (two patients), scrotum,
adrenals, spleen and kidney.
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sprimary metastatic disease. In all of those patients, the primary
tumour had been left in situ whereas 11 (23%) patients had
recurrent disease after previous surgery intending to cure the
primary.
Feasibility and safety
The median number of completed cycles was 4 (range 0–6 cycles).
Adherence to the planned doses of both oxaliplatin and 5-FU was
high. Dose reductions of one or both agents to o80% of initial
doses were required in o10% of patients. The median adminis-
tered cumulative dose of oxaliplatin was 800mgm
 2.
All grade 1/2 treatment-related adverse events observed in more
than 5% of patients are listed in Table 2. While it affected 67% of
patients, sensory neuropathy was generally mild. All grade 3/4
treatment-related adverse events are listed in Table 2. The most
common grade 3/4 events (affecting 45% of patients) were
diarrhoea, deep vein thrombosis, neutropenia and nausea. Of note,
stomatitis and sensory neuropathy 4grade 2 were not reported in
any of the patients.
Serious adverse events (SAEs) were reported in 14 patients. Two
SAEs, one case of septic diarrhoea with neutropenia and one
of stroke were fatal. Both deaths occurred during the first two
treatment cycles. As there were no other early deaths within
the first 2 months after study entry, the 60-day mortality rate
was 4.2%.
Efficacy
Tumour response was evaluable according to RECIST criteria
in 45 patients. Three (6%) patients who did not undergo the
first follow-up tumour assessment due to early death or pre-
mature termination of therapy (patient preference) were included
in the intention-to-treat analyses as nonevaluable subjects. There
were two (4%) complete responses and 24 (50%) patients achieved
a partial remission, resulting in an overall response rate of 54%
(95% CI, 39–69%). Eight (17%) patients had stable disease and
11 (23%) had progressive disease at the first follow-up tumour
assessment.
A total of 25 (52%) patients received second- and third-line
chemotherapies: 13 irinotecan-based, seven taxane-based, three
platinum-based, one epirubicin, one etoposide, and four investi-
gational drugs. Two patients underwent secondary palliative
surgery and one patient was treated with external beam radiation
therapy.
Median OS was 11.4 months (95% CI, 8.0–14.9 months,
Figure 1). Median TTP was 6.5 months (95% CI, 3.9–9.2 months,
Figure 2). Median follow-up is 18.1 months (range 11.2–26.2
months).
Table 2 Treatment-related adverse events
No. of patients (%)
Event Grade 1/2 Grade 3/4
Anaemia 21 (44%) 2 (4%)
Neutropenia 6 (13%) 4 (8%)
Febrile neutropenia NA 2 (4%)
Thrombocytopenia 7 (15%) 1 (2%)
Diarrhoea 17 (35%) 8 (17%)
Constipation 4 (8%) 0 (0%)
Stomatitis 7 (15%) 0 (0%)
Nausea 33 (69%) 3 (6%)
Emesis 13 (27%) 1 (2%)
Fatigue 21 (44%) 2 (4%)
Deep vein thrombosis NA 7 (15%)
Tumour bleeding NA 2 (4%)
Cardiac ischaemia NA 1 (2%)
Pneumonia NA 1 (2%)
Fever 4 (8%) 0 (0%)
Alopecia 7 (15%) NA
Sensory neuropathy 32 (67%) 0 (0%)
NA¼not applicable.
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Figure 2 Kaplan–Meier curve for time to progression in all patients
(n¼48).
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Figure 1 Kaplan–Meier curve for overall survival in all patients (n¼48).
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sDISCUSSION
Oxaliplatin combinations have become the mainstay of systemic
treatment for advanced gastrointestinal tumours. As a result of the
data from randomised phase III trials showing superiority over
former standard regimens (de Gramont et al, 2000; Giacchetti et al,
2000; Andre ´ et al, 2004a; Goldberg et al, 2004), oxaliplatin plus
5-FU/FA has been approved in many countries for the palliative
treatment of stage IV colorectal cancer and the adjuvant therapy of
stage III colon cancer. Moreover, there is increasing evidence from
phase II studies that oxaliplatin combinations have significant
activity in other gastrointestinal tumours such as pancreatic cancer
(Louvet et al, 2002b; Ducreux et al, 2004) and biliary tract adeno-
carcinoma (Andre ´ et al, 2004b). In combination with radiation
therapy, oxaliplatin and fluoropyrimidines result in promising
tumour remissions in locally advanced oesophageal and rectal
cancer (Freyer et al, 2001; Khushalani et al, 2002; Ro ¨del et al, 2003).
In advanced gastric cancer, two previously published phase II
studies have shown consistent results regarding the activity of
biweekly oxaliplatin-5–FU/FA combinations. These regimens
induced objective tumour responses in 43 and 45% of patients,
respectively, and were associated with a median survival of 9.6 and
8.6 months, respectively (Louvet et al, 2002a; Al-Batran et al,
2004). A study from Taiwan assessed the activity of oxaliplatin-5-
FU/FA given on days 1 and 8, repeated every 3 weeks. This regimen
induced an objective tumour reponse in 56% of the evaluable
patients. The median TTP and survival were 5.2 and 10.0 months,
respectively (Chao et al, 2004). Although data from phase III trials
have not yet been presented, in daily practice the combination of
oxaliplatin plus 5-FU/FA is increasingly used by many oncologists
for the treatment of advanced gastric cancer.
The objective of this study was to assess the efficacy of weekly
oxaliplatin plus 5-FU/FA given 4 out of 5 weeks (FUFOX regimen)
as first-line treatment for metastatic gastric and oesophagogastric
adenocarcinoma. Leading to an objective response rate of 54%, the
activity of FUFOX exceeded the expectations of the trial. This
unexpectedly high activity of FUFOX seems to translate into a
meaningful clinical benefit, as indicated by the median survival
time of 11.4 months.
One might assume that these promising efficacy results are
attributable to a patient selection bias. To encounter this well-
known phenomenon in phase II testing, selected study centres
included two university hospitals, two community hospitals and
five private practices. This represents the typical treatment facilities
for cancer patients in Germany. As in three studies on oxaliplatin
plus 5-FU/FA in gastric cancer previously published by the French
group (Louvet et al, 2002a), the Taiwan group (Chao et al, 2004)
and the Frankfurt group (Al-Batran et al, 2004), the majority of
patients in our study presented with a good performance status and
the median age of 62 years was in the same range as in the three
previous trials. Of note, all patients included in our study presented
with metastatic disease. Consequently, none of them underwent
secondary curative treatment. In contrast, the French group
reported on seven of 54 (13%) patients with locally advanced
disease and on eight (15%) patients undergoing complementary
surgery or chemoradiation with curative intent.
The three other mentioned studies do not report on the
frequency of second-line chemotherapy in their study populations.
In our study, the use of second- and even third-line therapies was
relatively frequent (450% of patients). The chosen regimens most
frequently included irinotecan or taxanes. Although no phase III
trial has yet defined the clinical benefit of second-line chemo-
therapy in gastric cancer, there is no doubt that second-line
treatment with the most recently available agents may be effective
in a considerable number of patients. Evidence from phase II trials
suggests that irinotecan-containing regimens may be particularly
active in this setting (Ajani et al, 2002; Assersohn et al, 2004).
Therefore, it is important to acknowledge that the use of second-
line chemotherapies may have positively influenced the survival
time in our study population.
Treatment compliance for the FUFOX regimen was very good
with a dose adherence to both oxaliplatin and 5-FU of 490%. As
already observed by the Taiwan and even more by the Frankfurt
group, avoiding the 5-FU bolus administration has led to a
dramatic reduction of haematological toxicity. In the French
regimen, which included a 5-FU bolus on day 1, the rate of grade 3/
4 neutropenia was 38%. This was associated with an 11% rate of
febrile neutropenia. Thus, in our study using weekly oxaliplatin/5-
FU as well as in the modified version of biweekly FOLFOX as used
by the Frankfurt group, bolus 5-FU was omitted. Consequently, the
rate of grade 3/4 neutropenia was below 10% and febrile
neutropenia occurred in less than 5% of the patients in both
studies. Compared with the other oxaliplatin/5-FU regimens
studied in gastric cancer, the rate of severe diarrhoea was relatively
high (17%) in our study. However, this is comparable with recently
reported findings with the FUFOX regimen in metastatic colorectal
cancer, where grade 3/4 diarrhoea affected 21% of patients
(Grothey et al, 2002). It would be worthwhile to investigate
whether administering a lower dose of FA, which can itself cause
diarrhoea, would reduce this rate.
Unfortunately, in our study, one patient died as a result of septic
diarrhoea and neutropenia. The investigators considered this death
to be treatment-related. However, the relationship between stroke
and death in another patient was judged to be uncertain by the
investigators. Nevertheless, these events highlight the importance of
careful monitoring of these highly vulnerable patients, even when a
generally well-tolerated chemotherapy regimen is administered.
As expected with oxaliplatin-containing regimens, neurotoxicity
affected the majority of patients. However, in contrast to studies
with the FOLFOX-6 regimen, where 21% of patients reported
functional impairment caused by sensory neuropathy with a
median administered oxaliplatin dose of 900mgm
 2 (Louvet et al,
2002a), the intensity of neuropathy observed in our trial, where the
median dose of oxaliplatin was 800mgm
 2, did not exceed mild to
moderate grades. This observation corresponds well with the
recently reported low rate of severe neuropathy with the weekly
FUFOX regimen in stage IV colorectal cancer (Grothey et al, 2002).
These observations indicate that weekly application of lower doses
of oxaliplatin may have advantages compared with biweekly
oxaliplatin-regimens in terms of neurotoxicity.
In conclusion, weekly oxaliplatin plus 5-FU/FA has a favourable
safety profile compared with previous data from studies of the
biweekly FUFOX regimen. This weekly FUFOX regimen results in a
high tumour response rate in first-line metastatic gastric cancer and
is associated with a promising OS time. Therefore, the weekly FUFOX
regimen can be recommended for phase III studies as well as a
combination partner for new investigational drugs in phase I/II trials.
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